Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee
Urah Micellar Glucosamine Cream (Twin Pack Offer)
Size: 50g tube
- Joint Health Champion:Leveraging clinical evidence, this product is verified to enhance joint health and mobility.
- Scientifically Proven:Developed by leading scientists and backed by rigorous research, Urah’s glucosamine cream offers a breakthrough solution for joint health, addressing the limitations of traditional oral supplements.
- Glucosamine Rich:Infused with premium-quality glucosamine, it’s formulated for superior joint care with 8% Optimal Miscellar Glucosamine Sulphate
- Effortless Application:Boasts a quick-absorbing, non-greasy formula ideal for hassle-free daily application.
- Shipping: Instant shipping with flat shipping rate.
- Return Policy: Our Return Policy ensures you have a seamless experience.
Urah Micellar Intensive Bodycare Cream Plus + (Twin Pack Offer)
Size: 50g tube
- Skin & Joint Omega-3 and Chondroitin: Infused with Omega-3 and Chondroitin, our cream enhances both skin hydration and joint health for comprehensive care.
- Scientifically Proven: Developed by leading scientists and backed by rigorous research, Urah’s Micellar Glucosamine cream offers a breakthrough solution for joint health, addressing the limitations of traditional oral supplements.
- Universal Hydration Formula: Enjoy our non-greasy, hydrating formula, perfect for all skin types, leaving skin nourished without a slick residue.
- Shipping: Instant shipping with a flat shipping rate.
- Return Policy: Our Return Policy ensures you have a seamless experience.
Urah Micellar Sporting Cream Plus + (Twin Pack offer)
Size: 50g tube
- Athlete-Specific Formulation: Tailored with Micellar Glucosamine, MSM, and Omega 3 to meet the high demands of athletic activity for superior joint and muscle support. . With 10% Optimal Miscellar Glucosamine Sulphate
- Rapid Recovery Support: Designed to facilitate swift muscle and joint recovery after exercise, enhancing your post-workout regimen.
- Proven Performance Enhancement: Clinically tested and proven to contribute positively to athletic performance, helping you achieve your best.
- Shipping: Instant shipping with flat shipping rate.
- Return Policy: Our Return Policy ensures you have a seamless experience.
ABSTRACT
Objective To determine the effect of glucosamine, chondroitin, or the two in combination on joint pain and on radiological progression of disease in osteoarthritis of the hip or knee.
Design Network meta-analysis. Direct comparisons within trials were combined with indirect evidence from other trials by using a Bayesian model that allowed the synthesis of multiple time points.
Main outcome measure Pain intensity. Secondary outcome was change in minimal width of joint space. The minimal clinically important difference between preparations and placebo was prespecified at-0.9 cm on a 10 cm visual analogue scale.
Data sources Electronic databases and conference proceedings from inception to June 2009, expert contact, relevant websites.
Eligibility criteria for selecting studies Large scale randomised controlled trials in more than 200 patients with osteoarthritis of the knee or hip that compared glucosamine, chondroitin, or their combination with placebo or head to head.
Results 10 trials in 3803 patients were included. On a 10 cm visual analogue scale the overall difference in pain intensity compared with placebo was -0.4 cm (95% credible interval-0.7 to-0.1 cm) for glucosamine,-0.3 cm (-0.7 to 0.0 cm) for chondroitin, and -0.5 cm (-0.9 to 0.0 cm) for the combination. For none of the estimates did the 95% credible intervals cross the boundary of the minimal clinically important difference. Industry independent trials showed smaller effects than commercially funded trials (P=0.02 for interaction). The differences in changes in minimal width of joint space were all minute, with 95% credible intervals overlapping zero.
Conclusions Compared with placebo, glucosamine, chondroitin, and their combination do not reduce joint pain or have an impact on narrowing of joint space. Health authorities and health insurers should not cover the costs of these preparations, and new prescriptions to patients who have not received treatment should be discouraged.
For full report, please click here